Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the 10 best biotech stocks with highest upside potential. On April 13, ...

SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ...

About OTX-TIC (travoprost implant) for Intracameral Use OTX-TIC is a bioresorbable intracameral implant containing micronized travoprost that is injected into the anterior chamber of the eye and is ...

Ocular Therapeutix to receive $12 million upfront fee and development and commercialization milestones and other payments of up to $91 million plus additional royalties on future product sales BEDFORD ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and ...

View Ocular Therapeutix Inc OCUL stock quote prices, financial information, real-time forecasts, and company news from CNN.

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best low priced biotech stocks to invest in. Ocular Therapeutix Inc.

Analysts' ratings for Ocular Therapeutix (NASDAQ:OCUL) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below provides a snapshot of their recent ratings, ...

Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular ...

(RTTNews) - Shares of Ocular Therapeutics, Inc. (OCUL), are up 23% in pre-market trading today, reflecting investor enthusiasm around the company's late-stage pipeline in retinal and glaucoma programs ...

Dextenza ® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year ...